Evidence map›Paper›PMID 31136769›Full record

ArticleUrology2019

Adoption of Abiraterone and Enzalutamide by Urologists.

Megan E V Caram, Samuel R Kaufman, Parth K Modi, Lindsey Herrel, Mary Oerline, Ryan Ross, Ted A Skolarus, Brent K Hollenbeck, Vahakn Shahinian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Megan E V CaramDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI; VA Health Services Research & Development, Center for Clinical Management and Research, VA Ann Arbor Healthcare System, Ann Arbor, MI. Electronic address: mveresh@med.umich.edu.
Samuel R KaufmanDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI.
Parth K ModiDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI.
Lindsey HerrelDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI.
Mary OerlineDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI.
Ryan RossDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI.
Ted A SkolarusVA Health Services Research & Development, Center for Clinical Management and Research, VA Ann Arbor Healthcare System, Ann Arbor, MI; Department of Urology, University of Michigan Medical School, Ann Arbor, MI.
Brent K HollenbeckDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI.
Vahakn ShahinianDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI; Department of Urology, University of Michigan Medical School, Ann Arbor, MI.

Funding

De-implementation of low value castration for men with prostate cancerR37CA222885 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAINI, SAMEER DEV, SKOLARUS, TED ALBERT · 2018 to 2023
$3.6M
Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spendingR01HS025707 · AHRQ · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2017 to 2021
$1.7M
Impact of the Dissemination of Surgical Technology on Cancer Surgery OutcomesF32CA232332 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MODI, PARTH KIRAN · 2018 to 2018
$74k
AHRQ HHS R01 HS025707NCI NIH HHS F32 CA232332NCI NIH HHS R37 CA222885NCI NIH HHS T32 CA180984
6 · The paper itself

Abstract

objectiveTo investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists.

methodsUsing the Medicare Part D Public Use Files from 2013 to 2016, we identified total abiraterone and enzalutamide prescriptions 2013-2016 and urologists who prescribed moderate to high volumes of these drugs. We then characterized the urologist practices of those urologists according to practice context (eg, single-specialty group) using data from the Centers for Medicare and Medicaid Services, and the geographic distribution of those providers.

resultsWe found abiraterone prescriptions increased from 71,423 in 2013 to a peak of 100,371 in 2015 and enzalutamide prescriptions continued to increase from 29,572 in 2013 to 100,980 in 2016. Prescriptions by urologists increased between 2013 and 2016 while prescriptions by other specialties plateaued. The number of moderate-high prescribing urologists increased from 98 (abiraterone) and 22 (enzalutamide) in 2013, to 301 (abiraterone) and 671 (enzalutamide) by 2016 with 1063 unique urologists prescribing moderate-high volumes of either drug between 2013 and 2016. Among urologists who prescribe androgen deprivation therapy, 5% were moderate-high prescribers of abiraterone and 12% of enzalutamide in 2016. The majority of moderate-high prescribing urologists were in single-specialty groups (70%).

conclusionUrologists are increasingly prescribing oral therapies for metastatic castration-resistant prostate cancer. Understanding the distribution of urologists specializing in castration-resistant prostate cancer therapeutics will help guide future interventions to optimize the care for this important patient population.

Indexed as

Practice Patterns, Physicians'UrologyAndrostenesBenzamidesDrug PrescriptionsHumansMaleMedicaidMedicareNitrilesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantUnited StatesabirateroneAndrostenesBenzamidesenzalutamideNitrilesPhenylthiohydantoin

Identifiers

PMID31136769
PMCPMC6711811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.